The controversial approval of an antisense drug for muscular dystrophy dominated news this quarter, with overall approvals down compared with recent years. Two biosimilars made it over the finish line at the US Food and Drug Administration (FDA), and the European Medicines Agency (EMA) approved a genetically modified allogeneic T-cell therapy for use in bone marrow/stem cell transplants. A slew of breakthrough designations included two gene therapies; December looks to be a busy month at the FDA.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
DeFrancesco, L. Drug pipeline: 3Q16. Nat Biotechnol 34, 1089 (2016). https://doi.org/10.1038/nbt.3731
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt.3731